Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Non-Small Cell Lung Cancer
Clinical trial register · Poland

Non-Small Cell Lung Cancer Trials in Poland, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2709 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2709
Studies in scope
all four open statuses
1380
Recruiting now
open to new participants
510
Lead sponsors
across recruiting studies
Top sites
Warsaw 33 Poznan 28 Gdansk 21 Olsztyn 17 Lodz 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC12 AstraZeneca8 Hoffmann-La Roche6 AbbVie4 BioNTech SE3 Bristol-Myers Squibb3 Eli Lilly and Company2 Summit Therapeutics2 Pfizer2 Daiichi Sankyo2 Xcovery Holdings, Inc.1 Amgen1 Nuvation Bio Inc.1 PDC*line Pharma SAS1 Dizal Pharmaceuticals1 Nuvalent Inc.1 Synthekine1 Prestige Biopharma Limited1 Revolution Medicines, Inc.1 Innate Pharma1 Gilead Sciences1 Genentech, Inc.1
Site location
Warsaw33 Poznan28 Gdansk21 Olsztyn17 Lodz17 Lublin14 Przemyśl11 Krakow10 Bydgoszcz10 Bialystok8 Prabuty7 Bystra5 Gliwice5 Koszalin5 Gda?sk4 Szczecin4 Radom3 Wroc?aw3 Tomaszów Mazowiecki3 Katowice3 Wroclaw3 Kielce3 Siedlce3 Konin2 Rzeszów2 Show all 40
All 40 locations
Target enrolment
to

Non-Small Cell Lung Cancer trials in Poland

56 of 2709 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
Hoffmann-La Roche
Phase 3
400
Bystra, Gda?sk, Kielce, Olsztyn, Warsaw, Wroc?aw
2026-10-06
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Przemyśl
2026-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Poznan, Warsaw, Lodz, Chęciny
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Przemyśl
2026-03-18
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Radom, Katowice, Kielce, Lodz, Lublin, Opole, Wroclaw, Tomaszów Mazowiecki
2026-01-06
Recruiting
AbbVie
Phase 2/3
490
Poznan, Krakow, Warsaw, Gdansk, Sosnowiec
2025-12-10
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Poznan, Lublin, Bydgoszcz
2025-11-05
Recruiting
Hoffmann-La Roche
Phase 3
600
Bystra, Gda?sk, Krakow, Lublin, Olsztyn, Poznan, Radom, Warsaw
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Rzeszów
2025-10-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Przemyśl, Gliwice, Olsztyn
2025-10-08
Recruiting
BioNTech SE
Phase 1/2
880
Gdansk, Krakow, Poznan, Tomaszów Mazowiecki
2025-09-22
Active, closed
Bristol-Myers Squibb
Phase 2
76
Warsaw, Prabuty, Lodz
2025-09-19
Recruiting
Pfizer
Phase 3
714
Poznan, Lublin, Warsaw, Gdansk, Gliwice, Lodz
2025-07-23
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Brzozów, Gdansk, Lublin, Szczecin
2025-07-17
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Gdansk, Lublin, Poznan, Skorzewo
2025-05-06
Recruiting
Merck Sharp & Dohme LLC
Phase 2
90
Poznan, Warsaw, Gdansk, Koszalin
2025-03-30
Recruiting
Summit Therapeutics
Phase 3
780
Gdansk, Lodz, Lublin, Poznan, Skorzewo
2025-02-27
Recruiting
BioNTech SE
Phase 2/3
1,580
Bialystok, Bydgoszcz, Gdansk, Gliwice, Katowice, Kielce, Koszalin, Krakow
2025-01-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Siedlce, Warsaw
2024-11-21
Recruiting
AstraZeneca
Phase 3
1,160
Bialystok, Biała Podlaska, Bydgoszcz, Bystra, Lodz, Lublin, Poznan, Warsaw
2024-11-18
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Konin, Poznan, Bydgoszcz, Warsaw, Koszalin, Prabuty, Lodz
2024-10-07
Active, closed
Hoffmann-La Roche
Phase 3
338
Gdansk, Warsaw, Wroc?aw
2024-09-23
Active, closed
Amgen
Phase 1
49
Gdansk, Gliwice, Krakow, Lodz, Lublin
2024-09-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Bydgoszcz, Grudziądz, Gorlice, Krakow, Poznań, Lublin, Warsaw, Przemyśl
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Gorlice, Krakow, Lublin, Warsaw, Przemyśl, Olsztyn
2024-05-24
Recruiting
AstraZeneca
Phase 3
582
Bystra, Olsztyn, Poznan, Warsaw
2024-04-29
Recruiting
AstraZeneca
Phase 3
675
Olsztyn, Poznan, Przemyśl, Warsaw
2024-04-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Poznan, Krakow, Lublin, Warsaw, Przemyśl, Bialystok, Gdansk, Prabuty
2024-04-03
Active, closed
Merck Sharp & Dohme LLC
Phase 2
147
Bydgoszcz, Warsaw, Koszalin, Szczecin
2023-12-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Poznan, Bydgoszcz, Krakow, Warsaw, Przemyśl, Bialystok, Gdansk, Olsztyn
2023-12-06
Active, closed
Summit Therapeutics
Phase 3
1,600
Bydgoszcz, Lodz, Poznan, Prabuty, Warsaw
2023-10-26
Recruiting
Innate Pharma
Phase 2
70
Bialystok, Krąków, Lublin, Poznan, Prabuty, Warsaw
2023-06-23
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Gda?sk, Krakow, Olsztyn
2023-06-20
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Gdansk, Poznan, Przemyśl, Warsaw
2022-12-13
Active, closed
Hoffmann-La Roche
Phase 3
68
Wroc?aw
2022-11-01
Recruiting
BioNTech SE
Phase 1
320
Gdansk, Olsztyn, Poznan, Warsaw
2022-06-17
Recruiting
AbbVie
Phase 3
768
Poznan, Warsaw, Rzeszów, Olsztyn, Lodz
2022-03-25
Active, closed
AstraZeneca
Phase 3
390
Poznan, Warsaw
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Bialystok, Gliwice, Katowice, Lodz, Warsaw, Wroclaw
2022-02-18
Active, closed
AstraZeneca
Phase 3
1,051
Bydgoszcz, Gdansk, Koszalin, Poznan, Siedlce, Tomaszów Mazowiecki, Warsaw
2022-02-07
Recruiting
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
DrugsPembrolizumab KEYTRUDA·Pemetrexed·Carboplatin
Synthekine
Phase 1/2
364
Gdansk, Lodz, Olsztyn
2022-01-25
Active, closed
Gilead Sciences
Phase 3
603
Konin, Lodz, Rzeszáw, Siedlce
2021-11-17
Active, closed
AbbVie
Phase 1
520
Poznan, Warsaw, Przemyśl, Olsztyn
2021-10-13
Active, closed
Nuvation Bio Inc.
Phase 2
217
Lodz, Poznan, Torun
2021-09-01
Active, closed
Daiichi Sankyo
Phase 3
605
Bialystok, Gdynia, Lublin, Olsztyn, Poznan, Prabuty, Słupsk, Warsaw
2020-12-21
Active, closed
AstraZeneca
Phase 3
358
Olsztyn
2020-12-16
Active, closed
Genentech, Inc.
Phase 1
498
Gdansk, Józefów
2020-07-29
Active, closed
Eli Lilly and Company
Phase 3
261
Gdansk, Warsaw
2020-02-17
Active, closed
Prestige Biopharma Limited
Phase 3
650
Warsaw
2019-11-15
Active, closed
PDC*line Pharma SAS
Phase 1/2
73
Gdansk
2019-09-10
Active, closed
AstraZeneca
Phase 3
825
Bialystok, Olsztyn, Warsaw
2018-12-06
Active, closed
AbbVie
Phase 2
270
Poznan, Warsaw, Przemyśl, Szczecin, Lodz
2018-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Poznan, Bydgoszcz, Bystra, Wroclaw, Prabuty, Lodz
2018-04-24
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Gda?sk, Olsztyn, Poznan, Warsaw
2017-09-22
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Gdansk
2016-06
Active, closed
Eli Lilly and Company
Phase 3
453
Gdansk, Lodz, Olsztyn, Radom, Szczecin
2014-10-03
Rows per page Showing 1–56 of 56
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-poland/condition/non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,709 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 56 of those studies listing the condition Non-Small Cell Lung Cancer.

How many Non-Small Cell Lung Cancer trials are recruiting in Poland?

29 of the 56 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Non-Small Cell Lung Cancer), 56 studies
PhaseStudiesRecruitingShare
Phase 3382067.9%
Phase 26210.7%
Phase 1417.1%
Phase 1/2437.1%
Phase 2/3437.1%

Most active sponsors

Lead sponsors with the most studies (Non-Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC128
AstraZeneca83
Hoffmann-La Roche63
AbbVie42
BioNTech SE33
Bristol-Myers Squibb32
Daiichi Sankyo21
Eli Lilly and Company20
Pfizer22
Summit Therapeutics21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.